Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma
| Image |  |
|---|---|
| Description | |
| Author/s |
author: Paolo Antonio Ascierto Christian U Blank Reinhard Dummer Dirk Schadendorf |
| Publication date | March 5, 2019 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |